Pharmaceutical companies have embraced Artificial Intelligence in drug research almost universally, yet few company executives expect AI to actually make drugs succeed, according to a Citi survey released on Tuesday.“The biggest risk to the AI-powered drug discovery thesis is not that AI fails to accelerate discovery,” said John Yung, head of Asia healthcare research at the US investment bank. “The stronger risk is that acceleration does not translate into better drugs or higher probability of success.”“It’s only through that translation that companies can turn AI-driven speed into profit, and patients into real beneficiaries,” Yung added.
SRCSouth China Morning Post
LANGEN
LEANCenter-Right
WORDS95
ENT5
WED · 2026-09-09 · 06:00 GMTBRIEF NSR-2026-0909-109939
NSR-2026-0909-109939News Report·EN·Technology
As China embraces AI, only 24% of US pharmaceutical execs bet on it for innovation
A recent Citi survey indicates that while pharmaceutical companies have widely adopted artificial intelligence for drug research, a significant majority of US pharmaceutical executives are not confident AI will lead to successful drug development. John Yung, head of Asia healthcare research at Citi, stated that the primary concern is not AI's ability to accelerate discovery, but rather whether this acceleration will result in improved drugs or a higher probability of success.
Julie ZhangSouth China Morning PostFiled 2026-09-09 · 06:00 GMTLean · Center-RightRead · 1 min
South China Morning PostFIG 01
Reading time
1min
Word count
95words
Sources cited
1cited
Entities identified
5entities
Quality score
100%
§ 01
Briefing Summary
AI-generatedNEWSAR · AI
A recent Citi survey indicates that while pharmaceutical companies have widely adopted artificial intelligence for drug research, a significant majority of US pharmaceutical executives are not confident AI will lead to successful drug development. John Yung, head of Asia healthcare research at Citi, stated that the primary concern is not AI's ability to accelerate discovery, but rather whether this acceleration will result in improved drugs or a higher probability of success. He emphasized that this translation is crucial for companies to profit and for patients to benefit from AI-driven speed. The survey's findings were released on Tuesday.
Confidence 0.85Sources 1Claims 4Entities 5
§ 02
Article analysis
Model · rule-basedFraming
Technology
Economic Impact
Tone
Measured
AI-assessed
CalmNeutralAlarmist
Factuality
0.70 / 1.00
Factual
LowHigh
Sources cited
1
Limited
FewMany
§ 03
Key claims
4 extracted01
Companies can only turn AI-driven speed into profit and patients into beneficiaries through the translation of AI acceleration into better drugs or higher success probability.
quoteJohn Yung
Confidence
1.00
02
The biggest risk to the AI-powered drug discovery thesis is not that AI fails to accelerate discovery, but that acceleration does not translate into better drugs or higher probability of success.
quoteJohn Yung
Confidence
1.00
03
Only 24% of US pharmaceutical executives expect AI to make drugs succeed.
statisticCiti survey
Confidence
0.90
04
Pharmaceutical companies have almost universally embraced artificial intelligence in drug research.
factual
Confidence
0.80
§ 04
Full report
1 min read · 95 words§ 05
Entities
5 identifiedKey playerOppositionContextPositiveNeutralNegative
People1
Organizations1
§ 06
Keywords & salience
8 termsdrug discovery
1.00
artificial intelligence
1.00
pharmaceutical companies
0.90
ai-powered drug discovery
0.80
innovation
0.70
probability of success
0.60
citi survey
0.50
healthcare research
0.40
§ 07
Topic connections
Interactive graph Network visualization showing 51 related topics
View Full Graph Person Organization Location Event|Click node to navigate|Edge numbers = shared articles